StemPar is a company focused on developing a pipeline of first-in-class cancer drugs that target solid tumors. Their approach involves disrupting the energy source of tumors and their defensive ability to regenerate. StemPar's lead program, SPS-201, targets an enzyme frequently expressed at high levels by tumors. By reducing NADH/ATP levels and increasing production of Reactive Oxygen Species (ROS), SPS-201 effectively depletes energy reserves of cancer cells. StemPar is dedicated to translating scientific advances into new cancer treatments.